share_log

Guggenheim Maintains Buy on Verve Therapeutics, Lowers Price Target to $55

Benzinga ·  Aug 15, 2023 11:09

Guggenheim analyst Seamus Fernandez maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and lowers the price target from $56 to $55.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment